Maggie L. Shaw

Marc S. Raab, MD, PhD, discusses the different ways that combination therapy that includes teclistamab can benefit patients with multiple myeloma.

Discover how the Hearing Loss Association of America advocates for hearing loss awareness and hearing health integration through a dialogue with Barbara Kelley, executive director.

AI can transform health care by processing vast data, enhancing decision-making, and addressing biases, but needs remain for transparency and human oversight.

Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, advocate for improved proactive management of myasthenia gravis (MG) for better patient outcomes.

New research highlights rising opioid use disorder (OUD) diagnoses among youth, emphasizing the need for improved screenings and mental health support.

The FDA has expanded sotatercept's indications for pulmonary arterial hypertension, following data showing significant drops in hospitalization and mortality risks.

Thorough eye exams in patients who have myasthenia gravis can detect concurrent autoimmune retinopathy and its complications.

Roflumilast 0.05% cream significantly reduces itch and improves atopic dermatitis in young children, explains Lawrence F. Eichenfield, MD.

The Hearing Loss Association of America advocates for early hearing loss detection, addressing mental health, and improving accessibility to enhance quality of life.

Patients successfully self-administer rozanolixizumab for generalized myasthenia gravis (gmG), preferring manual push delivery over infusion pumps in a phase 3 trial.

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on cardiotoxicity, explains Rakendu Rajendran, MBBS.

The LINKER-SMM1 trial shows promising results for linvoseltamab in treating high-risk smoldering multiple myeloma with a favorable safety profile, notes Paula Rodríguez-Otero, MD, PhD.

Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, focus on the best and most effective methods of engaging patients who have myasthenia gravis throughout their journey.

Research highlights the need for diverse data on drug efficacy in atopic dermatitis to address barriers to treatment for patients with skin of color, notes Elain Siegfried, MD.

A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial disparities and high costs.

WHO's latest report shows alarming trends in antimicrobial resistance, highlighting urgent global challenges and the need to improve surveillance and treatment.

Experts discuss the importance of initiating blinatumomab treatment for acute lymphoid leukemia in academic centers for optimal patient care.

Kelley L. Julian, PharmD, BCOP, discusses optimizing myeloma care, addressing barriers in access to intravenous immunoglobulin and innovative therapies at Huntsman Cancer Institute.

Arthritis is not one disease, and it has an impact that extends far beyond the well-known osteoarthritis or rheumatoid arthritis.

Raj Chovatiya, MD, PhD, MSCI, describes how delgocitinib offers a long-term solution for chronic hand eczema, transforming treatment beyond traditional corticosteroids.

Efgartigimod shows promising efficacy over IV immunoglobulin in treating impending myasthenic crisis in patients with myasthenia gravis.

UC Davis Health enhances patient care through a shared services center, ensuring continuity of care and optimizing pharmacy growth strategies.

UPMC's innovative pilot program combines medically tailored meals and nutrition education to tackle chronic disease and improve community health outcomes.

The European Respiratory Society (ERS) Congress fosters collaboration among global experts, advancing respiratory health and promoting equality in medicine.

Roflumilast cream 0.05% gains FDA approval for young children, offering a safe, effective treatment for mild to moderate atopic dermatitis.

Primary aldosteronism is often overlooked in hypertension. Educating providers and utilizing tools can enhance screening and treatment effectiveness, emphasizes Vivek Bhalla, MD, Stanford.

Social inequalities significantly impact COPD and PH outcomes, highlighting the need for systemic health care solutions, emphasizes Lucilla Piccari, MD, PhD, Hospital del Mar.

The MajesTEC-5 trial shows teclistamab's impressive efficacy in achieving MRD-negative status in newly diagnosed transplant-eligible patients, explains Marc S. Raab, MD, PhD.

Research reveals strong connections between muscle strength and cognitive function in patients with COPD, highlighting the potential for rehabilitation strategies.

Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, explore how understanding MG subtypes and patient characteristics enhances targeted therapy and personalized treatment.